Showing results (1241-1250 of 1,458) with videos related to

Sort By:
Pageof 146
Science Advances|December 7, 2019
Elucidating the active δ-opioid receptor crystal structure with peptide and small-molecule agonistsTobias Claff, Jing Yu, Véronique Blais, et al.
Journal of Alzheimer'S Disease : JAD|September 24, 2016
How Different are Quality of Life Ratings for People with Dementia Reported by Their Family Caregivers from Those Reported by the Patients Themselves?Louis Jacob, Ji Won Han, Tae Hui Kim, et al.
Liver Cancer|March 27, 2025
Dynamic Peripheral T-Cell Analysis Identifies On-Treatment Prognostic Biomarkers of Atezolizumab plus Bevacizumab in Hepatocellular CarcinomaJi Won Han, Min Woo Kang, Soon Kyu Lee, et al.
JAMA Network Open|April 4, 2025
Cytochrome P450 2C19 Genotypes and Clopidogrel in Patients With Ischemic Stroke: A Nonrandomized Clinical TrialYo Han Jung, Tae-Jin Song, Jinkwon Kim, et al.
Nature Structural & Molecular Biology|May 30, 2018
Structural basis for signal recognition and transduction by platelet-activating-factor receptorCan Cao, Qiuxiang Tan, Chanjuan Xu, et al.
Nature Communications|May 18, 2017
Crystal structure of a multi-domain human smoothened receptor in complex with a super stabilizing ligandXianjun Zhang, Fei Zhao, Yiran Wu, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|January 21, 2010
Expression of class III beta-tubulin correlates with unfavorable survival outcome in patients with resected non-small cell lung cancerYoungil Koh, Bogun Jang, Sae-Won Han, et al.
Journal of Reproductive Immunology|July 1, 2020
COVID-19 and immunomodulation treatment for women with reproductive failuresJoanne Kwak-Kim, Kuniaki Ota, Nayoung Sung, et al.
The Journal of Investigative Dermatology|May 19, 2024
Twin Prime Editing Mediated Exon Skipping/Reinsertion for Restored Collagen VII Expression in Recessive Dystrophic Epidermolysis BullosaBenjamin J Steinbeck, Xin D Gao, Amber N McElroy, et al.
The Lancet. Oncology|March 21, 2018
Modified XELIRI (capecitabine plus irinotecan) versus FOLFIRI (leucovorin, fluorouracil, and irinotecan), both either with or without bevacizumab, as second-line therapy for metastatic colorectal cancer (AXEPT): a multicentre, open-label, randomised, non-inferiority, phase 3 trialRui-Hua Xu, Kei Muro, Satoshi Morita, et al.
Pageof 146